Endothelin-1 (ET-1) and asymmetric dimethylarginine (ADMA) play a major role in tumor growth and metastasis. Our aim was to determine whether there is any association between these endothelial parameters and tumor markers with the clinical outcome of bevacizumab-treated metastatic colorectal cancer (mCRC) patients in terms of response and survival. Pretreatment serum levels of ET-1, ADMA, carcinoembryonic antigen (CEA), and carbohydrate antigen (CA) 19-9 were measured in 36 chemotherapy-naive mCRC patients treated with first-line bevacizumab-based therapy. Additionally, after first cycle of treatment, serum levels of these parameters were reanalyzed. Lower baseline serum ET-1 and ADMA levels were observed in patients responding to bevacizum...
Objective: Angiogenesis represents a key element in the pathogenesis of malignancy. There are no rob...
IF 5.008International audienceAnti-EGFR therapy and antiangiogenic therapies are used alone or in co...
Background: Different antiangiogenics are currently indicated in the second-line treatment of metast...
Endothelin-1 (ET-1) and asymmetric dimethylarginine (ADMA) play a major role in tumor growth and met...
Objective The present study evaluated the profile of endoglin (CD105) and vascular endothelial growt...
AIM: To identify suitable biomarkers of response to bevacizumab (BV) - it remains an open question. ...
Abstract BACKGROUND: Arterial hypertension occurring during antiangiogenic therapy has been correla...
BACKGROUND: The combination of chemotherapy with the vascular endothelial growth factor (VEGF) antib...
BACKGROUND: Bevacizumab prolongs progression-free survival (PFS) in patients with metastatic colorec...
Purpose: Patients with metastatic colorectal cancer (mCRC) receiving all three active drugs (Irinote...
PURPOSE: Patients with metastatic colorectal cancer (mCRC) receiving all three active drugs (iri...
Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metas...
Background: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and target...
argeting vascular endothelial growth factor (VEGF) pathway represents a successful strategy in the t...
The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imp...
Objective: Angiogenesis represents a key element in the pathogenesis of malignancy. There are no rob...
IF 5.008International audienceAnti-EGFR therapy and antiangiogenic therapies are used alone or in co...
Background: Different antiangiogenics are currently indicated in the second-line treatment of metast...
Endothelin-1 (ET-1) and asymmetric dimethylarginine (ADMA) play a major role in tumor growth and met...
Objective The present study evaluated the profile of endoglin (CD105) and vascular endothelial growt...
AIM: To identify suitable biomarkers of response to bevacizumab (BV) - it remains an open question. ...
Abstract BACKGROUND: Arterial hypertension occurring during antiangiogenic therapy has been correla...
BACKGROUND: The combination of chemotherapy with the vascular endothelial growth factor (VEGF) antib...
BACKGROUND: Bevacizumab prolongs progression-free survival (PFS) in patients with metastatic colorec...
Purpose: Patients with metastatic colorectal cancer (mCRC) receiving all three active drugs (Irinote...
PURPOSE: Patients with metastatic colorectal cancer (mCRC) receiving all three active drugs (iri...
Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metas...
Background: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and target...
argeting vascular endothelial growth factor (VEGF) pathway represents a successful strategy in the t...
The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imp...
Objective: Angiogenesis represents a key element in the pathogenesis of malignancy. There are no rob...
IF 5.008International audienceAnti-EGFR therapy and antiangiogenic therapies are used alone or in co...
Background: Different antiangiogenics are currently indicated in the second-line treatment of metast...